Abstract
The American Surgery of Bone Mineral Research (ASBMR) in 2007 defined MRONJ as “necrotic bone area exposed to the oral environment with more than eight weeks of permanence, in the presence of chronic treatment with Bisphosphonates (BP), in the absence of radiation therapy to the head and neck”.
Historically, the first drugs associated with the condition were BP, which led to coining of the term MRONJ. However, scientist need to include other drugs in the etiopathogenesis of osteonecrosis, such as other antiresorptive: Denosumab (DS) and antiangiogenic agents. MRONJ treatment is controversial nowadays and depend on Stages of the illness. Some authors recommend high toilettes and resection bone so other, prefer atraumatic therapies focused in antiseptic agents and interdisciplinary (dentist-physician) control.
The most common antiseptic agents used are Povidone Iodine, Rifamycin, Cetyl pyridinium chlorid and Chlorhexidine. Alcohol preparations have the fastest onset of action, followed by chlorhexidine and then povidone iodine. However, residual antimicrobial activity is greatest with chlorhexidine. Formulations that contain both chlorhexidine and alcohol combine the rapid onset of alcohol with the persisting effects of chlorhexidine.
Reference19 articles.
1. 1. Khan AA, Morrison A, Hanley DA, Felsenberg D, Laurie KC, Felice OR, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015; 30: 03-23.
2. 2. Fleisher KE; Kontio R; Otto S; Antiresortive drug-related ostenecrosis of the jaw (ARONJ) - a guide to research. AOCMF; 2016.
3. 3. Picardo SN, Rodriguez Genta SA, Rey EA. Osteonecrosis maxilar asociada a bifosfonatos en pacientes osteoporóticos. Revista Española de Cirugía Oral y Maxilofacial. 2015; 37: 103-107.
4. 4. Steel BJ. Management of Medication-related Osteonecrosis of the Jaw (MRONJ) risk in patients due to commence anti-resorptive/anti-angiogenic drugs - how should pre-drug-treatment dental preventive care be organized? Community Dent Health. 2019; 36: 244-254.
5. 5. Gámez Font R, Martínez García ML, Olmos Martínez JM. Osteochemonecrosis of the Jaws due to Bisphosphonate Treatments. Update. Med Oral Patol Oral Cir Bucal. 2008; 13: 318-324.